1.
Product Overview
2.
Research Methodology
3.
Executive Summary
4.
Impact of COVID-19 on Global Monkeypox Therapeutics
Market
5.
Voice of Customer
5.1.
Commonly Observed Symptoms of Monkeypox
5.2.
Monkeypox Prevalence, By Gender
5.3.
Monkeypox Prevalence, By Age Group
5.4.
Monkeypox Prevalence, By Region
6. Global Monkeypox
Therapeutics Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin
(VIG))
6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers,
Others)
6.2.3. By Company (2021)
6.2.4. By Region
6.3.
Product Market Map
7. North America
Monkeypox Therapeutics Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Treatment
7.2.2. By End User
7.2.3. By Country
7.3.
North America: Country Analysis
7.3.1. United States Monkeypox
Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Treatment
7.3.1.2.2.
By End User
7.3.2. Canada Monkeypox
Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Treatment
7.3.2.2.2.
By End User
8. Europe Monkeypox
Therapeutics Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Treatment
8.2.2. By End User
8.2.3. By Country
8.3.
Europe: Country Analysis
8.3.1. United Kingdom
Monkeypox Therapeutics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Treatment
8.3.1.2.2.
By End User
8.3.2. Germany Monkeypox
Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Treatment
8.3.2.2.2.
By End User
8.3.3. France Monkeypox
Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Treatment
8.3.3.2.2.
By End User
8.3.4. Belgium Monkeypox
Therapeutics Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Treatment
8.3.4.2.2.
By End User
8.3.5. Netherlands
Monkeypox Therapeutics Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Treatment
8.3.5.2.2.
By End User
8.3.6. Sweden Monkeypox
Therapeutics Market Outlook
8.3.6.1.
Market Size & Forecast
8.3.6.1.1.
By Value
8.3.6.2.
Market Share & Forecast
8.3.6.2.1.
By Treatment
8.3.6.2.2.
By End User
8.3.7. Italy Monkeypox
Therapeutics Market Outlook
8.3.7.1.
Market Size & Forecast
8.3.7.1.1.
By Value
8.3.7.2.
Market Share & Forecast
8.3.7.2.1.
By Treatment
8.3.7.2.2.
By End User
8.3.8. Spain Monkeypox
Therapeutics Market Outlook
8.3.8.1.
Market Size & Forecast
8.3.8.1.1.
By Value
8.3.8.2.
Market Share & Forecast
8.3.8.2.1.
By Treatment
8.3.8.2.2.
By End User
9. Asia-Pacific
Monkeypox Therapeutics Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Treatment
9.2.2. By End User
9.2.3. By Country
9.3.
Asia-Pacific: Country Analysis
9.3.1. Australia Monkeypox
Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Treatment
9.3.1.2.2.
By End User
9.3.2. Singapore Monkeypox
Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Treatment
9.3.2.2.2.
By End User
10. Middle East and
Africa Monkeypox Therapeutics Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Treatment
10.2.2. By End User
10.2.3. By Country
10.3.
MEA: Country Analysis
10.3.1. Nigeria Monkeypox
Therapeutics Market Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Treatment
10.3.1.2.2.
By End User
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
13.
Competitive Landscape
13.1.
Company Profiles
13.1.1. Company Details
13.1.2. Financials (As
reported)
13.1.3. Key Market Focus and
Geographical Presence
13.1.4. Pricing of Target
Products
13.1.5. Market positioning
13.2.
Chimerix Inc.
13.3.
SIGA Technologies, Inc.
13.4.
Emergent BioSolutions Inc.
13.5.
Bavarian Nordic A/S
13.6.
Hetero Drugs Limited
13.7.
Mylan N.V.
13.8.
Piramal Enterprises Limited
13.9.
Olon S.p.A.
13.10.
Teva Pharmaceutical Industries Limited
13.11.
CIDIC Company Limited
14. Strategic
Recommendations
(Note: The
companies list can be customized based on the client requirements.)